Skip to main content
European Commission logo
Enterprise Europe Network

A UK SME developing a platform technology using novel small molecules to inhibit the proliferation of cancer is seeking a commercial subcontractor to test these innovative molecules in preclinical trials in an animal model of cancer.

Summary

Profile Type
Business request
POD Reference
BRGB20240105015
Term of Validity
5 January 2024 - 4 January 2025
Company's Country
United Kingdom
Type of partnership
Commercial agreement
Targeted Countries
All countries
Contact the EEN partner nearest to you for more information.
Find my local partner

General information

Short Summary
R&D company, who has developed a novel class of small molecules offering a unique mechanism of action specifically designed to inhibit cell proliferation in highly aggressive cancers, starting with triple-negative breast cancer. It has collated strong proof of concept data that the molecules illustrate favourable efficacy, safety, and pharmacokinetic profiles in vitro and seeks commercial collaborators, capable and certified to test the molecules in the preclinical animal trials.
Full Description
The UK SME is a cutting-edge biotech company spun out from Oxford Brookes University in 2022, following a successful bid to Innovate UK for £300k. The company’s focus is on the development of innovative therapies to address unmet medical needs in oncology. Leveraging groundbreaking research and robust platform technology, the UK SME is poised to make a significant impact in the field of cancer treatment. The company’s mission is to revolutionise cancer care by developing targeted therapies that halt the proliferation of high mortality cancer cells. Its novel class of small molecules offers a unique mechanism of action, specifically designed to inhibit cell proliferation in highly aggressive cancers, starting with triple-negative breast cancer (TNBC), and then expanding to other difficult-to-treat cancers like squamous cell carcinoma of the head and neck, colorectal cancer, non-small-cell lung cancer, and multiple myeloma. The company’s technology capitalises on the identification of a vulnerability in cancer cells that was the result of more than two decades of intense investigations in the study of cancer.
The company’s technology addresses this unmet medical need, offering a potential breakthrough in inhibiting cancer cell proliferation. The UK SME unique disruptive approach is a more effective way to halt the cancer cells’ growth and the type of molecular interactions it affects is anticipated to less likely cause undesired side effects. Our innovation will help alleviate the burden of cancer healthcare by developing a product to manage aggressive forms of breast cancer and in turn other types of tumours, contributing to the enhancement of the well-being of the human population and fostering sustainable communities.
The company’s invention represents a promising approach for developing new treatments for cancer. The technology is developed to TLR4, thus the UK SME is seeking commercial subcontractors who have the facilities and expertise to conduct preclinical trials testing the lead compounds’ effectiveness, toxicity and pharmacokinetics in an animal model of cancer that will inform the company of the compound’s predicted treatment outcome in patients (efficacy), and identify and characterise all toxicities associated with the compound in order to predict adverse events in people (safety) for informed risk assessment.
Stage of Development
Under development
Sustainable Development Goals
Goal 3: Good Health and Well-being
IPR description
The UK SME is seeking subcontractors to conduct preclinical trials testing the lead compounds’ effectiveness, toxicity, pharmacokinetics in an animal model of cancer, starting with a pilot study in a mouse model of triple negative breast cancer that will inform the UK SME of the compound’s predicted efficacy and safety profile in humans. By conducting such studies will help identify potential safety risks such as toxicity or drug-drug interactions, determine optimal dosing and predict the pharmacokinetic profile in a human. The UK SME is seeking subcontractors that are compliant with the Animals Scientific Procedure Act 1986 if based in the UK or are compliant with the national and international regulations if based in Europe or are compliant with the Directive 2010/63/EU as amended if a European Union Member State.

Partner Sought

Expected Role of a Partner
The UK SME is seeking a subcontractor built of a team of preclinical experts who have extensive expertise and state-of-the-art-facilities and techniques to deliver high quality results. The company seeks a subcontractor consisting of a team of dedicated scientists who will work closely with the company during all stages of the preclinical development process to ensure the best approach is undertaken for the studies conducted that will also help the company make informed decisions about the development of its drugs. The UK SME is seeking subcontractors that are compliant with the Animals Scientific Procedure Act 1986 if based in the UK or are compliant with the national and international regulations if based in Europe or are compliant with the Directive 2010/63/EU as amended if a European Union Member State
Type and Size of Partner
SME 11-49SME <=10SME 50 - 249R&D InstitutionBig company
Type of partnership
Commercial agreement

Call details

Coordinator required
Yes

Dissemination

Technology keywords
06002002 - Cellular and Molecular Biology006001007 - Diseases06001005 - Diagnostics, Diagnosis06001012 - Medical Research006001002 - Care and Health Services
Market keywords
005001008 - Diagnostic test products and equipment05001007 - Other diagnostic
Targeted countries
All countries